



Article Long-Term Effects of Very Low Dose Particle Radiation on Gene Expression in the Heart: Degenerative Disease Risks

Venkata Naga Srikanth Garikipati¹, Arsen Arakelyan^{2,3}, Eleanor A. Blakely⁴, Polly Y. Chang⁵, May M. Truongcao⁶, Maria Cimini⁶, Vandana Malaredy⁶, Anamika Bajpai⁶, Sankar Addya⁷, Malik Bisserier⁸, Agnieszka Brojakowska⁸, Abrisham Eskandari⁸, Mary K. Khlgatian⁸, Lahouaria Hadri⁸, Kenneth M. Fish⁸, Raj Kishore⁶, and David A. Goukassian^{8,*}

- ¹ Department of Emergency Medicine, Dorothy M Davis Heart and Lung Research Institute, Wexner Medical School, The Ohio State University, Columbus, OH 43210, USA; venkata.garikipati@osumc.edu
- ² Bioinformatics Group, The Institute of Molecular Biology, The National Academy of Sciences of the Republic of Armenia, Yerevan 0014, Armenia; arakelyanaa@gmail.com
- ³ PathVerse, Yerevan 0014, Armenia
- ⁴ Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA; eablakely@jbl.gov
- ⁵ SRI International, Menlo Park, CA 94025, USA; polly.chang@sri.com
- ⁶ Center for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA; maycao@temple.edu (M.M.T.); maria.cimini@temple.edu (M.C.); tuj39930@temple.edu (V.M.); nmkbjp18@gmail.com (A.B.); raj.kishore@temple.edu (R.K.)
- ⁷ Kimmel Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA; sankar.addya@jefferson.edu
- ⁸ Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; malik.bisserier@mssm.edu (M.B.); agnieszka.brojakowska@mssm.edu (A.B.); abrisham.eskandari@icahn.mssm.edu (A.E.); mkhlgatian@gmail.com (M.K.K.);
- lahouaria.hadri@mssm.edu (L.H.); kenneth.fish@mssm.edu (K.M.F.)
- Correspondence: david.goukassian@mssm.edu; Tel.: +1-212-824-8917

Abstract: Compared to low doses of gamma irradiation (γ -IR), high-charge-and-energy (HZE) particle IR may have different biological response thresholds in cardiac tissue at lower doses, and these effects may be IR type and dose dependent. Three- to four-month-old female CB6F1/Hsd mice were exposed once to one of four different doses of the following types of radiation: γ -IR ¹³⁷Cs (40-160 cGy, 0.662 MeV), ¹⁴Si-IR (4-32 cGy, 260 MeV/n), or ²²Ti-IR (3-26 cGy, 1 GeV/n). At 16 months post-exposure, animals were sacrificed and hearts were harvested and archived as part of the NASA Space Radiation Tissue Sharing Forum. These heart tissue samples were used in our study for RNA isolation and microarray hybridization. Functional annotation of twofold up/down differentially expressed genes (DEGs) and bioinformatics analyses revealed the following: (i) there were no clear lower IR thresholds for HZE- or γ -IR; (ii) there were 12 common DEGs across all 3 IR types; (iii) these 12 overlapping genes predicted various degrees of cardiovascular, pulmonary, and metabolic diseases, cancer, and aging; and (iv) these 12 genes revealed an exclusive non-linear DEG pattern in ¹⁴Si- and ²²Ti-IR-exposed hearts, whereas two-thirds of γ -IR-exposed hearts revealed a linear pattern of DEGs. Thus, our study may provide experimental evidence of excess relative risk (ERR) quantification of low/very low doses of full-body space-type IR-associated degenerative disease development.

Keywords: heart; space radiation; gene expression; gamma radiation; NASA; female mice

1. Introduction

During future exploration-type space missions, astronauts could be exposed to doses of space-type radiation (IR) (~0.4–0.5 Gy) from galactic cosmic rays (GCR), especially during Mars missions, where astronauts would not have access to comprehensive health care services for at least 2–3 years [1,2]. Emerging evidence suggests that during deep-space missions, each cell in an astronaut's body could be traversed by a proton every 3–4 days,



Citation: Garikipati, V.N.S.; Arakelyan, A.; Blakely, E.A.; Chang, P.Y.; Truongcao, M.M.; Cimini, M.; Malaredy, V.; Bajpai, A.; Addya, S.; Bisserier, M.; et al. Long-Term Effects of Very Low Dose Particle Radiation on Gene Expression in the Heart: Degenerative Disease Risks. *Cells* **2021**, *10*, 387. https://doi.org/ 10.3390/cells10020387

Academic Editor: Wayne Carver Received: 5 January 2021 Accepted: 8 February 2021 Published: 13 February 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). helium nuclei every few weeks, and high-charge-and-energy (HZE) nuclei (e.g., C, O, Si, Ti, Fe) every few months [3,4]. Since most experienced astronauts are middle-aged (average age is 46 years, range is 33 to 58 years of age), they are at risk for developing severe, adverse cardiovascular (CV) and other degenerative diseases both during long space missions as well as later in life [5]. Others and our own NASA-funded published data provided experimental evidence of the effects of low-dose proton and HZE-IR on the short- and long-term alteration in cardiac function, cardiomyocyte morphology, and the associated underlying molecular mechanisms [6–10]. Here, we provide for the first time the transcriptome analysis of mouse hearts exposed to low and very low doses of gamma-(¹³⁷Cs), silicon- (¹⁴Si), and titanium- (²²Ti) ion irradiation (IR). Animal numbers per each irradiated group were selected by power analysis to assure statistical significance after low dose radiation exposures. Our results show that 16 months after a single low- or very low dose IR exposure, the gene expression in the heart tissue is significantly differentially regulated compared to the sham-treated, non-irradiated controls, suggesting there are long-term effects on dysregulation of varying molecular pathways that are associated with various degrees of CV, pulmonary, and metabolic diseases, as well as biological processes, including abnormal circadian rhythms, cancer, Hutchinson-Gilford progeria syndrome, etc. Thus, our study may provide additional experimental evidence of the level of gene expression for estimation of excess relative risk (ERR) for the development of CV and other diseases due to exposure to low or very low doses of whole-body space-type IR.

2. Materials and Methods

2.1. Animal Procedures

We used NASA Space Radiation Tissue Sharing Forum–archived samples of female CB6F1/Hsd mice from experiments conducted and published by Drs. Polly Chang and Eleanor Blakely for evaluation of IR-induced carcinogenesis in the mouse Harderian gland [11]. Detailed experimental protocols were previously published by Chang et al. [11]. Briefly, female CB6F1/Hsd mice were obtained from Harlan Laboratories Inc. (Indianapolis, IN, USA). For each study, 100–120-day-old female mice were shipped directly from the vendor to Brookhaven Laboratory Animal Facility (BLAF; Upton, New York, NY, USA) approximately 1 week before irradiation. Mice were randomized by weight immediately prior to whole-body particle IR exposure. After exposure, mice were shipped to the animal facility at the Lawrence Berkeley National Laboratory (LBNL) and maintained for 16 months. The 16-month period was chosen as it coincides with the time frame for Harderian gland tumor development. All procedures were compliant with the standards of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and approved by the Animal Care and Use Committees at Lawrence Berkeley National Laboratory (Berkeley, CA, USA), Brookhaven National Laboratory (BNL) (Upton, NY, USA), and SRI International (Menlo Park, CA, USA, which included established diurnal room lights on/off cycles).

2.2. Irradiation Procedures

Detailed experimental protocols were previously published by Chang et al. [11]. Briefly, female CB6F1/Hsd mice (n = 5/group) were irradiated with low and very low doses of HZE-IR at the NASA Space Radiation Laboratory (NSRL) at the BNL. Dosimetry studies, including depth–dose and dose–uniformity measurements, were conducted by beamline physicists. Unanesthetized animals were briefly held in plastic boxes ($40 \times 40 \times 73$ mm³) containing numerous holes to provide abundant airflow. Animals were irradiated for <1 min with a single, full-body HZE-IR dose (≤ 0.5 Gy) of 260 MeV/n silicon (¹⁴Si, linear energy transfer [LET] ≈ 70 keV/µm) and 1000 MeV/n titanium (²²Ti, LET ≈ 100 keV/µm). As another control group, a separate cohort of animals was irradiated with ¹³⁷Cs γ -ray that served as a low-LET reference radiation. Table 1 depicts beam energies, doses, and LET used in these studies. Control sham-treated animals were placed in clear plastic holders for

equivalent exposure times but were not irradiated. Similar to irradiated mice, control mice were also maintained unanesthetized.

Ion	Dose (cGy)	Energy (MeV/n)	Entrance LET (keV/μ)
	0		
	40		
¹³⁷ Cs	80	0.662	0.8
	120		
	160		
	0		
	4		
¹⁴ Si	8	260	70
	16		
	32		
	0		
	3		
²² Ti	6.5	1000	100
	13		
	26		

 Table 1. Ionizing radiation types. Beam energies, doses, and LET used in this study.

2.3. Tissue Collection and Sample Processing

Animals were sacrificed 16 months after a single dose of full-body IR with the corresponding ions and doses (Table 1). Gross observations of all tissues were conducted during necropsy and recorded. Hearts from control non-tumor-bearing mice were snap-frozen in liquid nitrogen by members of Drs. Chang and Blakely's research team [11] and archived as part of NASA's Space Radiation Tissue Sharing Forum. These archived heart tissue samples were utilized for our current gene expression study.

2.4. RNA Extraction

Total RNA was isolated from snap-frozen heart tissues using the RNeasy Mini Kit (Qiagen, Germantown, MD, USA) according to the manufacturer's protocol. Briefly, heart tissues were lysed and homogenized in the presence of a highly denaturing guanidine-thiocyanate-containing buffer, which immediately inactivates RNAses to ensure purification of intact RNA. Ethanol (70%) was added to provide appropriate binding conditions. The homogenates were then applied to a RNeasy Mini spin column, where the total RNA binds to the membrane and contaminants are efficiently washed away. High-quality RNA was eluted using molecular-grade water (RNAse/DNAse free). RNA concentrations were assessed using a Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Quality assessment was performed using Agilent 2200 TapeStation (Agilent Technologies, Palo Alto, CA, USA) prior to qRT-PCR and microarray analysis.

2.5. Microarray Analysis

Linear messenger RNA (mRNA) amplification was achieved using the Affymetrix WT-Plus kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's guidelines. Briefly, 100 ng of RNA from each sample was used to generate amplified and biotinylated complimentary DNA (cDNA) according to the guidelines of the Affymetrix WT-Plus kit. Target denaturation was performed at 99 °C for 5 min. cDNA was then hybridized to the Clariom S Mouse Array (Affymetrix, Santa Clara, CA, USA) for 16 h at 45 °C while being rotated at 60 rpm. Arrays were then washed and stained using GeneChip Fluidics Station 450 (Affymetrix, CA, USA) and subsequently scanned with Affymetrix Gene Chip Scanner 3000 using Command Console software. Signal space transformation (SST) normalization of raw data was performed using Expression Console software v 1.41. (provided by Affymetrix). GeneSpring 14.9 software (Agilent, Santa Clara, CA, USA) was used to identify differentially expressed transcripts between experimental and control

groups. Of note, samples were processed for microarrays in two batches: first, 3 samples for each condition (n = 36) and then 2 samples for each treatment condition (n = 24) for a total of 60 samples representing 5 animals per each ion/dose.

2.6. Batch Examination and Correction

Principal components analysis (PCA) was used to identify batch effects by examining patterns in plots of the first two principal components. Three methods for batch effect adjustment were used: (1) Combat implemented in the sva R package [12], (2) remove BatchEffect implemented in the limma R package [13], and (3) harman implemented in the Harman R package [14]. Changes in batch effect contribution after adjustment were assessed using the pvca R package [15].

2.7. Microarray Data Preprocessing

Background correction, conversion of signal intensity to log2-transformed expression values, and quantile normalization were performed on microarray raw CEL files using the Robust MultiArray Average (RMA) algorithm implemented in the limma R package [13]. Microarray probe IDs were converted to Entrez IDs using annotate and clariomsmousetranscriptcluster.db R packages.

2.8. Analysis of Differential Gene Expression

Differentially expressed genes (DEGs) between control and each irradiated group were identified using limma package [13]. Relaxed adjusted *p*-values of <0.25 were selected as a cutoff for up- and downregulated genes, which is reasonable for finding an adequate amount of DEGs for further validation and functional gene set analysis. Functional annotation of DEGs was performed with the enrichR R package, which contains 35 human and rodent gene set libraries (Supplementary Table S1) [16]. The Enrichr gene set enrichment method is based on a combined score calculated from a proportional test (Fisher's exact test) and the *z*-score of deviation from the expected rank for each term in each gene set library (see original publications for details [16]). Adjusted *p*-values of < 0.05 were selected as a cutoff for over-represented gene sets. The lists of all differentially expressed genes are provided in Supplementary Table S2.

2.9. Analysis of Dose-Dependent Changes in Gene Expression

To evaluate the patterns of gene expression changes in response to increasing doses of irradiation, we performed linear and non-linear regression analysis using functions from stats and splines R packages, respectively. For each gene, both linear and non-linear regression models were fitted. The fit was considered significant if the model-adjusted *p*-value was less than 0.25, and the fit type was assigned based on the highest *R*-squared value between two models for each gene.

2.10. Portrayal of Transcriptome Landscapes

Transcriptome analysis was performed using the self-organizing map (SOM) machine learning approach implemented in the oposSOM R package [17]. The SOM approach represents dimension reduction that translates 20,426 gene expression profiles in 72 samples into 1600 metagenes, each representing a cluster of genes with similar profiles of expression across samples. The metagene expression values of each sample are visualized (expression portrayal) by arranging them into a two-dimensional 40×40 grid and using maroon to blue colors corresponding to maximum to minimum expression values in each of the portraits [18]. The oposSOM R package also offers a variety of tools for downstream analyses, including function mining, modular feature selection, sample stratification, diversity analysis, and phenotype mapping [17]. The limma-batch-effect-corrected gene expression data were used as input data. For these serial analyses, all control animals were combined into one group.

2.11. qRT-PCR

The expression levels of the Arntl, Cdkn1a, Per3 Slc41a3, and Bhlhe41 transcripts were measured by quantitative real-time polymerase chain reaction (qRT-PCR). Briefly, total cellular RNA was isolated from mouse heart tissues across all samples using the miRNeasy Mini Kit (Qiagen), as previously described. The High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368814) was used to generate cDNA according to the manufacturer's instructions. Quantitative RT-PCR was performed using an Applied Biosystems 7700 apparatus. The relative expression levels of the target gene mRNAs were calculated by the comparative C_T method. Differences in C_T values were calculated for each target mRNA after subtracting the mean value of 18S rRNA (relative expression = $2^{-\Delta CT}$) [19]. Data were normalized using 18S ribosomal RNA (rRNA). Forward and reverse primer sequences are provided in Table 2.

Table 2. Quantitative RT-PCR primers used in this study.

Gene	Primer
	Probe-/56-FAM/ACC TGC TCC/ZEN/AGT GTT TCC TCA TCA/3IABkFQ/
ARNTL	R-ATC CAC AGC TAG CCC AAA C
	F-CCA CCT CAG AGC CAT TGA TAC
	Probe-/56-FAM/CTG GTT TCT/ZEN/GTG CCT CCC TGA CTG/3IABkFQ/
Slc41a3	R-CAC TGA GGA CAT GAG GGA AAG
	F-CTT CTT CCT GGA CTG GTT ACT G
	Probe-/56-FAM/CAG CCT AGA/ZEN/ACA GGG ATG GCA GTT/3IABkFQ/
Cdkn1a	R-GAG TCG GGA TAT TAC GGT TGA G
	F-CCA GCT AGG ATG ACA GTG AAG
	Probe-/56-FAM/AGC CGG AAG/ZEN/GTC TCC TTC ATC ATT/3IABkFQ/
PER3	R-TGG ACT CGT TCG GAC TTT ATG
	F-GCA CTC AGA ACG GAG AGT ATG
	Probe-/56-FAM/AAC CGG AAG /ZEN/CCA CAG CTC ATA CAT/3IABkFQ/
Bhlhe41	R-TGC CTG ACT TTC TTC CCT TAC
	F-TGA CTG TGA CAA GCT GAC TG

2.12. Gene Enrichment Analyses

After the identification of the 12 common regulated genes (Spon2, Adam19, Arntl, Cdkn1a, Cry2, Per2, Per3, Wee1, Rcan1, Slc41a3, Errfi1, and Bhlhe41) across all 3 radiation types (¹³⁷Cs, ¹⁴Si, and ²²Ti), gene enrichment analysis was repeated using the ENRICHR resource (http://amp.pharm.mssm.edu/Enrichr/, accessed 09/2020), an integrative webbased gene list enrichment analysis tool that includes the 2019 Kyoto Encyclopedia of Genes and Genomes (KEGG) Mouse database and the ChEA 2016 gene library for identification of enriched terms and upstream transcription factors, respectively. The clustergrammer shows heatmaps of enriched terms as columns.

2.13. Statistical Analysis of qPCR Results

Data are presented as the mean \pm standard error of the mean (SEM). mRNA expression levels of Arntl, Cdkn1a, Per3, Slc41a3, and Bhlhe41 between non-exposed and exposed animals were analyzed using one-way analysis of variance with the Bonferroni correction for comparisons between >2 groups. Statistical analysis was performed using GraphPad Prism 6, version 6.07 (GraphPad Software, Inc., La Jolla, CA, USA). Differences were considered statistically significant at p < 0.05.

3. Results

3.1. Data Collection, Pre-Processing, and Mapping

Since samples were processed for microarray analyses in two separate batches, we first performed a batch effect assessment. PCA clearly showed that samples were divided into two clusters. To minimize the observed effects on gene expression values, we performed batch effect removal using methods described in the Batch Examination and Correction section of Materials and Methods. Assessment of batch-related effects with principal variance component analysis showed the best adjustment and was done by limma (Supplementary Figure S1A–E), and these data were used for differential gene expression analysis.

Next, we performed a portrayal of transcriptome landscapes for studied groups using the SOM approach (Supplementary Figure S2). This method projects gene expression data onto a two-dimensional grid of 40×40 pixels (SOM portraits) and allows for visualization of clusters of up- and downregulated genes as spot-like structures on a map of red or blue color, respectively. Inspection of deregulated spot distribution on the group-centered SOM portraits demonstrated that radiation exposure triggers variations in the transcriptome landscape compared to untreated animals. Moreover, it could be noted that the highest variability of gene expression changes is associated with the particle type (Supplementary Figures S2 and S3). Less pronounced yet visible differences in transcriptome landscapes were also associated with particle exposure dosage. As these results warrant further exploration, we performed a detailed analysis of DEGs and functional annotation analysis.

3.2. Different Gene Expression in Mouse Heart Tissue Following ¹³⁷Cs Irradiation

We evaluated DEGs in mouse hearts exposed to different doses of ¹³⁷Cs-IR (Figure 1A–G). The analysis revealed changes in DEGs in particle-exposed animals vs. controls (adjusted p < 0.25). We identified a clear dose-dependent increase in the number of DEGs in ¹³⁷Cs-IR-exposed mouse hearts. The highest number of DEGs (529 genes, 241 upregulated and 288 downregulated) was observed after the highest dose, 160 cGy ¹³⁷Cs-IR (Figure 1A–C,G and Supplementary Spreadsheet_Cs_DEG_Up_Down). Conversely, the lowest number of DEGs was seen in 40 cGy ¹³⁷Cs-IR-exposed mouse hearts, where we found 47 DEGs, of which 32 were upregulated and 15 downregulated (Figure 1A-D and Supplementary Table S3). After 80 cGy ¹³⁷Cs-IR, we identified 104 DEGs, of which 60 were upregulated and 44 downregulated (Figure 1A–C,E and Supplementary Table S3). After 120 cGy ¹³⁷Cs-IR, we found 157 DEGs, of which 75 were upregulated and 82 downregulated (Figure 1A-C,F and Supplementary Table S3). Overall, 10 overlapping genes were common for all four doses of ¹³⁷Cs-IR (Figure 1B). Of these 10 genes, 8 were upregulated (Dbp, Gstt2, Pik3ip1, Tspan4, Tcap, Stc2, P2rx7, and Nr1d2) and 2 were downregulated (Errfi1 and Arntl). These 10 common genes are implicated in the modulation of circadian rhythms [20–22], regulation of muscle cell differentiation and locomotor activity [23], cardiac hypertrophy [24], metabolism [23,25,26], oxidative stress [27–29], inflammation [30–32], and tumorigenesis [23,33-36].

3.3. Different Gene Expression in Mouse Heart Tissue Following ¹⁴Si Irradiation

Next, we evaluated the gene expression changes in mouse hearts subjected to ¹⁴Si-IR (260 MeV/n) exposure at varying doses. The analysis revealed significant changes in DEGs (adjusted p < 0.25). Notably, the highest number of DEGs (72 genes, 40 upregulated and 32 downregulated) was observed in ¹⁴Si-IR-exposed mice after the lowest dose of 4 cGy (Figure 2A–D and Supplementary Table S4), with no overlapping genes between any of the varying ¹⁴Si-IR doses (Figure 2B). In mouse hearts exposed to 8 cGy ¹⁴Si-IR, we found 39 DEGs, of which 20 were upregulated and 19 downregulated (Figure 2A–C,E and Supplementary Table S4). Surprisingly, we did not find any DEGs in the 16 cGy ¹⁴Si-IR groups (Figure 2A–C), whereas after 32 cGy of ¹⁴Si-IR, we detected 43 DEGs, of which 18 were upregulated and 25 downregulated (Figure 2A–C,F and and Supplementary Table S4).



Figure 1. Different gene expression in mouse heart tissue following ¹³⁷Cs-gamma irradiation: (**A**) bar graphs showing differentially expressed genes in the mouse heart tissue at different ¹³⁷Cs (Cs, cesium) doses and (**B**) Venn diagram depicting the number of differentially expressed genes in the mouse hearts across different doses of ¹³⁷Cs irradiation. Colors in the diagram represent genes putatively affected by the following ¹³⁷Cs dose exposure: blue circles correspond to 40 cGy, green circles to 80 cGy, yellow circles to 120 cGy, and purple circles to 160 cGy. (**C**) Table depicting the number of up- and downregulated genes at different ¹³⁷Cs-IR doses in the heart tissue and (**D**–**G**) heat maps showing differentially expressed genes at different ¹³⁷Cs-IR doses. Relative expression values are indicated on the color key and increase in value from blue to red (*n* = 5/group).





C Number of Up and Down regulated DEGs per ¹⁴Si Dose

lon/Dose Direction	¹⁴ Si - 4	¹⁴ Si - 8	¹⁴ Si - 16	¹⁴ Si - 32
Up-regulated	40	20	0	18
Down-regulated	32	19	0	25



Figure 2. Different gene expression in mouse heart tissue following ¹⁴Si irradiation: (**A**) bar graphs showing differentially expressed genes in mouse heart tissue after exposure to different ¹⁴Si (Si, silicon) doses and (**B**) Venn diagram depicting the number of differentially expressed genes in mouse hearts across different doses of ¹⁴Si irradiation exposure. Colors in the diagram represent genes putatively affected by the following ¹⁴Si dose exposure: blue circles correspond to 4 cGy, green circles to 8 cGy, yellow circles to 16 cGy, and purple circles to 32 cGy. (**C**) Table depicting the number of up- and downregulated genes at different ¹⁴Si-IR doses in the heart tissue and (**D**–**F**) heat maps showing differentially expressed genes at different ¹⁴Si-IR oses. Relative expression values are indicated on the color key and increase in value from blue to red (n = 5/group).

3.4. Different Gene Expression in Mouse Heart Tissue Following ²²Ti Irradiation

Further analysis of DEGs in mouse hearts subjected to different doses of ²²Ti-IR (1000 MeV/n) revealed significant changes in DEGs (adjusted p < 0.25). The highest number of DEGs (460 genes, 234 upregulated and 226 downregulated) was observed after a very low dose of 6.5 cGy ²²Ti-IR (Figure 3A–C,E and and Supplementary Table S5). We identified 49 overlapping DEGs between the 6.5 and 13 cGy ²²Ti-IR groups (Figure 3B). At the lowest dose of 3 cGy ²²Ti-IR, we found only 2 DEGs, of which 1 was upregulated and 1 downregulated (Figure 3A–D and and Supplementary Table S5). In the hearts of 13 cGy ²²Ti-IR-exposed mice, we found 108 DEGs, of which 55 were upregulated and 53 downregulated (Figure 3A–C,F and Supplementary Table S5). Surprisingly, we did not detect any DEGs with ≥twofold change in mouse hearts subjected to the highest dose of 26 cGy ²²Ti-IR (Figure 3A–C). Similar to our previous findings after different doses of ¹⁴Si-IR, we did not find any overlapping DEGs between the four ²²Ti-IR doses (Figures 2B and 3B).

A Total Number of DEGs per ²²Ti Dose







C Number of Up and Down regulated DEGs per ²²Ti Dose

lon/Dose Direction	²² Ti - 3	²² Ti - 6.5	²² Ti - 13	²² Ti - 26
Up-regulated	1	234	55	0
Down-regulated	1	226	53	0



Figure 3. Different gene expression in mouse heart tissue following ²²Ti irradiation: (**A**) bar graphs showing differentially expressed genes in mouse heart tissue after exposure to different ²²Ti (Ti, titanium)-IR exposure. Colors in the diagram represent genes putatively affected by the following ²²Ti dose exposure: blue circles correspond to 3 cGy, green circles to 6.5 cGy, yellow circles to 13 cGy, and purple circles to 26 cGy. (**B**) Venn diagram depicting the number of differentially expressed genes in mouse hearts across different doses of Ti radiation exposure. Colors in the diagram represent genes putatively affected by the following Ti dose exposure: blue circles correspond to 3 cGy, green circles to 6.5 cGy, yellow circles to 13 cGy, and purple circles to 26 cGy. (**B**) Venn diagram depicting the number of differentially expressed genes in mouse hearts across different doses of Ti radiation exposure. Colors in the diagram represent genes putatively affected by the following Ti dose exposure: blue circles correspond to 3 cGy, green circles to 6.5 cGy, yellow circles to 13 cGy, and purple circles to 26 cGy. (**C**) Table depicting the number of up- and downregulated genes after exposure to different ²²Ti-IR doses in the heart tissue and (**D**–**F**) heat maps showing differentially expressed genes at different ²²Ti-IR doses. Relative expression values are indicated on the color key and increase in value from blue to red (*n* = 5/group).

3.5. Common Differentially Expressed Genes across All Radiation Types

We identified 12 overlapping genes that were common for all three types of IR and were detected in at least one or more IR doses for each ion (Figure 4A–E). These 12 overlapping genes are associated with a variety of biological and physiological processes, including food intake, body weight, sleep alterations, circadian rhythms, inhibition of angiogenesis and myogenesis, locomotor activity, metabolism, gluconeogenesis, and lipogenesis behavior, as well as susceptibility to chronic diseases such as hypertension, diabetes, obesity, infection, and cancers of different organs. With regard to their subcellular localization, the majority of the 12 common DEGs are distributed in the nucleus (83%), cytosol (42%), plasma membrane (25%), and extracellular (47%) (Table 3). These genes are associated with the regulation of many processes within the organelles, including kinase binding (Cdkn1a, Cry2, Errfi1, Per2, Per3), transcription regulating activities (Arntl, Bhlhe41, Cry2, Per2, Spon2), histone deacetylase binding (Bhlhe41, Per2), SH3 domain binding (Adam19,

Errfi1), nuclear hormone receptor binding (Cry2, Per2), protein kinase activity (Wee1), and cation transmembrane transporters (Slc41a3) (Table 4). The top intracellular pathways of the 12 overlapping genes were associated with circadian rhythms and entrainment (Arntl, Cry2, Per2, Per3, Bhlhe41), the cell cycle (Cdkn1a, Wee1), the oxytocin signaling pathway (Cdkn1a, Rcan1), and transcriptional misregulation in cancer (Cdkn1a, Per2) (Table 5).



В

Entrez Gene ID	Gene Name	Description	¹³⁷ Cs*	¹⁴ Si*	²² Ti*
100689	Spon2	Spondin 2, extracellular matrix protein	1 dose 2 doses		1 dose
11492	Adam19	A disintegrin and metallopeptidase domain 19 (meltrin beta)	3 doses	3 doses	1 dose
11865	Arntl	Aryl hydrocarbon receptor nuclear translocator-like	4 doses	3 doses	1 dose
12575	Cdkn1a	Cyclin-dependent kinase inhibitor 1A (P21)	3 doses	1 dose	2 doses
12953	Cry2	Cryptochrome 2 (photolyase-like)	3 doses	2 doses	1 dose
18627	Per2	Period circadian clock 2	2 doses	3 doses	1 dose
18628	Per3	Period circadian clock 3	3 doses	3 doses	2 doses
22390	Wee1	WEE 1 homolog 1 (S. pombe)	1 dose	3 doses	1 dose
54720	Rcan1	Regulator of calcineurin 1	2 doses	2 doses	1 dose
71699	Slc41a3	Solute carrier family 41, member 3	2 doses	1 dose	2 doses
74155	Errfi1	ERBB receptor feedback inhibitor 1	4 doses	1 dose	1 dose
79362	Bhlhe41	Basic helix-loop-helix family, member e41	3 doses	3 doses	1 dose

* - indicates number of doses for which adjusted p was less than 0.25



Figure 4. Overlapping differentially expressed genes: (**A**) Venn diagram depicting the overlap of enrichment terms amongst three different radiation exposure groups (137 Cs, 14 Si, and 22 Ti) compared to the control group. In the diagram, blue circles represent genes putatively affected by long-term 137 Cs exposure, yellow circles represent genes influenced by 14 Si exposure, and green circles represent those affected by 22 Ti exposure. (**B**) Table depicting 12 commonly expressed genes in one or more of all radiation-type exposures and (**C**–**E**) microarray data analysis showing heat maps of the 12 overlapping commonly expressed genes in different radiation groups/doses. Relative expression values are indicated on the color key and increase in value from blue to red (n = 5/group).

Gene Name	Extracellular	Plasma Membrane	Nucleus	Cytosol	Human Protein Atlas
Spon2	Y				Plasma proteins, predicted membrane proteins, predicted secreted proteins
Adam19		Y	Y		Plasma proteins, predicted membrane proteins
Arntl			Y		predicted intracellular proteins, transcription factors
Cdkn1a			Y	Y	Cancer-related genes, predicted intracellular proteins
Cry2	Y		Y	Y	Predicted intracellular proteins
Per2			Y		Disease-related genes, predicted intracellular proteins
Per3			Y	Y	Disease-related genes, predicted intracellular proteins
Wee1			Y		Cancer-related genes, enzymes, plasma proteins, Predicted
Rcan1			Y	Y	Predicted intracellular proteins
Slc41a3		Y			Predicted membrane proteins, transporters
Errfi1		Y	Y	Y	Predicted intracellular proteins
Bhlhe41			Y		Predicted intracellular proteins, transcription factors

Table 3. Cellular localization of 12 overlapping differentially expressed genes.

Table 4. Molecular signaling activities of 12 overlapping differentially expressed genes.

Term Description	Genes
RNA polymerase II-specific DNA-binding transcription factor binding	Arntl, Bhlhe41, Cry2, Per2
Kinase binding	Cdkn1a, Cry2, Errfi1, Per2, Per3
Transcription regulatory region sequence-specific DNA binding	Arntl, Bhlhe41, Cry2, Per2
Histone deacetylase binding	Bhlhe41, Per2
SH3 domain binding	Adam19, Errfi1
Nuclear hormone receptor binding	Cry2, Per2
Transcription regulator activity	Arntl, Bhlhe41, Cry2, Per2
Signaling receptor binding	Arntl, Cry2, Per2, Spon2
Protein kinase activity	Wee1
Nucleic acid binding	Rcan1
Cation transmembrane transporter activity	Slc41a3

Table 5. Intracellular pathways involvement of 12 overlapping differentially expressed genes.

	Spon2	Adam19	Arntl	Cdkn1a	Cry2	Per2	Per3	Wee1	Rcan1	Slc41a3	Errfi1	Bhlhe41
Circadian rhythm			+		+	+	+					+
ErbB signaling pathway				+								
HIF-1 signaling pathway				+								
FoxO signaling pathway				+								
Cell cycle, circadian regulated				+				+				
p53 signaling pathway				+								
PI3K-Akt signaling pathway				+								
Cellular senescence				+								
JAK-STAT signaling pathway				+								
Oxytocin signaling pathway				+					+			
Transcriptional misregulation in cancer				+		+						
Circadian entrainment						+	+					
Acute myeloid leukemia						+						
Human Immuno-deficiency virus 1 infection								+				
Thyroid hormone signaling pathway									+			

3.6. Microarray Analysis and Validation

To validate our microarray analysis findings of the 12 overlapping DEGs across the three different radiation groups (Figure 4A–F), we tested five DEGs, namely period circadian regulator 3 (Per3), basic helix-loop-helix family member E41 (Bhlhe41), cyclin-dependent kinase inhibitor 1A (Cdkn1a), solute carrier family 41 member 3 (Slc41A3), and aryl hydrocarbon receptor nuclear translocator like (Arntl), by qRT-PCR. Our qRT-PCR analysis revealed that only Per3 was found significantly regulated in all conditions (Figure 5A–E vs. Figure 4C–E). We also found that Bhlhe41, Cdkn1a, Slc41A3, and Arntl were all significantly upregulated after ¹³⁷Cs-IR exposure in a dose–response manner. However, only Bhlhe41 was found to be upregulated in the ²²Ti-IR group at high doses. Our results also showed that Cdkn1 and Slc41A3 were significantly downregulated post-¹⁶Si-IR exposure, while Arntl was found to be significantly upregulated at lower doses (⁸Si).



Figure 5. qRT-PCR validation of 5 of 12 common differentially expressed genes across all radiation types: mNA expression of (**A**) Per3, (**B**) Bhlhe41, (**C**) Cdkn1a, (**D**) Slc41a3, and (**E**) Arntl was measured by qRT-PCR in heart tissue (n = 3 heart/group). Data were normalized using 18S rRNA. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared to control groups. Per3, period circadian regulator 3; Bhlhe41, basic helix-loop-helix family member E41; Cdkn1a, cyclin-dependent kinase inhibitor 1A; Arntl, aryl hydrocarbon receptor nuclear translocator like; Slc41a3, solute carrier family 41 member 3.

D

F

3.7. Gene Enrichment Analysis of 12 Common DEGs

To further identify potentially compromised biological pathways, we performed a comprehensive gene set enrichment analysis for the 12 common genes (Spon2, Adam19, Arntl, Cdkn1a, Cry2, Per2, Per3, Wee1, Rcan1, Slc41a3, Errfi1, and Bhlhe41) across all three radiation types using Enrichr and pathway databases such as the 2019 Kyoto Encyclopedia of Genes and Genomes (KEGG) for Mouse (Figure 6). KEGG pathway enrichment analysis revealed that pathways associated with circadian rhythms, cancer (thyroid, bladder, endometrial, non-small-cell lung cancer), the cell cycle, and the oxytocin signaling pathway were the most enriched by these DEGs (Figure 6A–C). We then evaluated these DEGs against the ChIP-X enrichment analysis (ChEA) gene set library to calculate enrichment for upstream transcription factors. The ChEA 2016 database is a gene set library that contains putative targets for transcription factors, based on reports profiling transcription factors binding to DNA in mammalian cells. This analysis identified 10 transcription factors (CLOCK, TCF21, AR, SALL4, SMAD2, SMAD3, PPAR, OCT4, CDX2, and CEBPB) that may be involved in the regulation of the 12 common DEGs across the three types of radiation (Figure 6D–F).

В

CRY2

NEGG 2								
Circadia	n rhythm							
Circadian entrainment								
Cell cycle								
Oxytocin signaling pathway								
Transcriptional misregulation in cancer								
Kaposi s	arcoma-associated herpesvirus infection							
Thyroid	cancer							
Bladder	cancer							
Endome	trial cancer							
Basal ce	carcinoma							
Index	Name	P-value	Adjusted p-value	Odds Ratio	Combined score			
Index 1	Name Circadian rhythm	P-value 4.202e-12	Adjusted p-value 1.273e-9	Odds Ratio 277.78	Combined score 7276.49			
Index 1 2	Name Circadian rhythm Circadian entrainment	P-value 4.202e-12 0.001550	Adjusted p-value 1.273e-9 0.2348	Odds Ratio 277.78 33.67	Combined score 7276.49 217.83			
Index 1 2 3	Name Circadian rhythm Circadian entrainment Thyroid cancer	P-value 4.202e-12 0.001550 0.02198	Adjusted p-value 1.273e-9 0.2348 0.9515	Odds Ratio 277.78 33.67 45.05	Combined score 7276.49 217.83 171.96			
Index 1 2 3 4	Name Circadian rhythm Circadian entrainment Thyroid cancer Cell cycle	P-value 4.202e-12 0.001550 0.02198 0.002378	Adjusted p-value 1.273e-9 0.2348 0.9515 0.2402	Odds Ratio 277.78 33.67 45.05 27.10	Combined score 7276.49 217.83 171.96 163.72			
Index 1 2 3 4 5	Name Circadian rhythm Circadian entrainment Thyroid cancer Cell cycle Bladder cancer	P-value 4.202e-12 0.001550 0.02198 0.002378 0.02433	Adjusted p-value 1.273e-9 0.2348 0.9515 0.2402 0.9215	Odds Ratio 277.78 33.67 45.05 27.10 40.65	Combined score 7276.49 217.83 171.96 163.72 151.06			
Index 1 2 3 4 5 6	Name Circadian rhythm Circadian entrainment Thyroid cancer Cell cycle Bladder cancer Oxytocin signaling pathway	P-value 4.202e-12 0.001550 0.02198 0.002378 0.02433 0.003696	Adjusted p-value 1.273e-9 0.2348 0.9515 0.2402 0.9215 0.2800	Odds Ratio 277.78 33.67 45.05 27.10 40.65 21.65	Combined score 7276.49 217.83 171.96 163.72 151.06 121.22			
Index 1 2 3 4 5 6 7	Name Circadian rhythm Circadian entrainment Thyroid cancer Cell cycle Bladder cancer Oxytocin signaling pathway Endometrial cancer	P-value 4.202e-12 0.001550 0.02198 0.002378 0.02433 0.003696 0.03426	Adjusted p-value 1.273e-9 0.2348 0.9515 0.2402 0.9215 0.2800 1.000	Odds Ratio 277.78 33.67 45.05 27.10 40.65 21.65 28.74	Combined score 7276.49 217.83 171.96 163.72 151.06 121.22 96.95			
Index 1 2 3 4 5 6 7 8	Name Circadian rhythm Circadian entrainment Thyroid cancer Cell cycle Bladder cancer Oxytocin signaling pathway Endometrial cancer Transcriptional misregulation in cancer	P-value 4.202e-12 0.001550 0.02198 0.002378 0.02433 0.003696 0.03426 0.005174	Adjusted p-value 1.273e-9 0.2348 0.9515 0.2402 0.9215 0.2800 1.000 0.3135	Odds Ratio 277.78 33.67 45.05 27.10 40.65 21.65 28.74 18.21	Combined score 7276.49 217.83 171.96 163.72 151.06 121.22 96.95 95.89			
Index 1 2 3 4 5 6 7 8 9	Name Circadian rhythm Circadian entrainment Thyroid cancer Cell cycle Bladder cancer Oxytocin signaling pathway Endometrial cancer Transcriptional misregulation in cancer Basal cell carcinoma	P-value 4.202e-12 0.001550 0.02198 0.002378 0.02433 0.003696 0.03426 0.005174 0.03716	Adjusted p-value 1.273e-9 0.2348 0.9515 0.2402 0.9215 0.2800 1.000 0.3135 1.000	Odds Ratio 277.78 33.67 45.05 27.10 40.65 21.65 28.74 18.21 26.46	Combined score 7276.49 217.83 171.96 163.72 151.06 121.22 96.95 95.89 87.10			

Earched Terms

CIIEA 2	.016		
CLOCK 2	20551151 ChIP-Seq 293T Human		
TCF21 2	6020271 ChIP-Seq SMOOTH MUSCLE Human		
AR 2191	5096 ChIP-Seq LNCaP-1F5 Human		
SALL4 1	8804426 ChIP-ChIP XEN Mouse		
SMAD2	189 <mark>55504 ChIP-ChIP HaCaT Human</mark>		
SMAD3	189 <mark>55504 ChIP-ChIP HaCaT Human</mark>		
PPAR 26	484153 Chip-Seq NCI-H1993 Human		
OCT4 18	692474 ChIP-Seq MEFs Mouse		
CDX2 22	108803 ChIP-Seq LS180 Human		
CEBPB 2	1427703 ChIP-Seq 3T3-L1 Mouse		
Index	Name	P-value	Adjusted p- value
1	CLOCK 20551151 ChIP-Seq 293T Human	5.703e-8	0.000036
2	TP63 17297297 ChIP-ChIP HaCaT Human	0.02374	0.41
3	THRA 23701648 ChIP-Seq CEREBELLUM Mouse	0.004956	0.12

Index	Name	P-value	Adjusted p- value	Odds Ratio	Combined score
1	CLOCK 20551151 ChIP-Seq 293T Human	5.703e-8	0.00003678	24.57	409.82
2	TP63 17297297 ChIP-ChIP HaCaT Human	0.02374	0.4139	41.67	155.85
3	THRA 23701648 ChIP-Seq CEREBELLUM Mouse	0.004956	0.1279	18.62	98.83
4	EGR1 19374776 ChIP-ChIP THP-1 Human	0.04006	0.4235	24.51	78.86
5	TRIM28 21343339 ChIP-Seq HEK293 Human	0.05270	0.4856	18.52	54.50
6	NUCKS1 24931609 ChIP-Seq HEPATOCYTES Mouse	0.004561	0.1226	8.50	45.83
7	KLF5 18264089 ChIP-ChIP MESCs Mouse	0.06010	0.5238	16.18	45.50
8	KLF2 18264089 ChIP-ChIP MESCs Mouse	0.06010	0.5168	16.18	45.50
9	KLF4 18264089 ChIP-ChIP MESCs Mouse	0.06066	0.5148	16.03	44.91
10	SALL4 18804426 ChIP-ChIP XEN Mouse	0.002268	0.3656	6.63	40.39



Figure 6. A comprehensive gene set enrichment analysis for the 12 common genes differentially regulated across all 3 radiation groups was performed using EnrichR and the Kyoto Encyclopedia of Genes and Genomes (KEGG) 2019 Mouse database and ChIP-X enrichment analysis (ChEA) gene set library. (A) Bar graphs (sorted by *p*-value ranking) represent the

significance of that specific gene set using the KEGG 2019 Mouse database. The brighter the color, the more significant that term. (**B**) The clustergrammer is sorted by combined scores (*p*-value and *z*-score) and shows heatmaps. Enriched terms are shown as columns and input genes as rows to understand the relationships between input genes and enriched terms. Cells in the matrix indicate whether a gene is associated with the indicated term. (**C**) The table shows a raw view of the data and is sorted by *p*-value. Terms, *z*-score, odds ratio, and combined score are indicated. (**D**) Bar graphs (sorted by *p*-value ranking) represent the significant the transcription factor (TF). (**E**) The clustergrammer is sorted by *p*-value and shows heatmaps of enriched terms as columns. Input genes are shown as rows to understand the relationships between the input genes and enriched TFs. Cells in the matrix indicate whether a gene is associated with the gene is associated with the predicted TF. (**F**) The table shows a raw view of the data and enriched terms as columns. Terms, *z*-score, odds ratio, and combined score are indicated.

Further enrichment analysis revealed that ¹⁴Si-IR exposure dysregulated 213 biological processes in the heart tissue, whereas ¹³⁷Cs-IR exposure alone affected 1040 biological processes, and ²²Ti-IR exposure dysregulated 302 biological processes. Interestingly, we found 61 overlapping biological processes that were common for all three radiation groups compared to controls (Figure 7A). Top hits for biological processes included abnormal circadian rhythm, colon cancer, Hutchinson–Gilford progeria syndrome, acute myocardial infarction, type 1 diabetes, etc. (Figure 7B).



Figure 7. Overlapping biological processes: (**A**) Venn diagram analysis of differentially expressed genes across all three different radiation exposure groups/doses compared to controls. In each paired test, the differentially expressed genes were identified as a log2 fold change and p < 0.05. In the diagram, blue circles represent genes putatively affected by long-term ¹³⁷Cs exposure, green circles represent genes influenced by ¹⁴Si exposure, and yellow circles represent genes that were putatively affected by ²²Ti exposure. (**B**) The table represents various biological processes that are common for all three radiation groups.

Finally, we were interested in understanding the extent of the genes and associated biological processes that were shared between particle doses causing the maximal effect (¹³⁷Cs at 160 cGy, ¹⁴Si at 4cGy, and ²²Ti at 6.5 cGy). The analysis showed little overlap in terms of up- or downregulated genes (Supplemental Figure S4A–D). Four upregulated overlapping gene sets were detected in all three conditions, and more when performing pairwise comparisons (Supplemental Figure S4A–D). While non-overlapping, each pairwise comparison revealed a considerable number of heart-disease-related gene sets, suggesting that particle irradiation may affect cardiac function through various mechanisms. No common downregulated gene sets were detected (Supplementary Table S6).

3.8. Regression Analysis of Common Differentially Expressed Genes across Radiation Type

Next, we assessed the 12 overlapping DEGs using dose-dependent regression analyses (see the Materials and Methods section for details). Our findings revealed an exclusive

non-linear differential gene expression pattern in ¹⁴Si- and ²²Ti-IR-exposed hearts, whereas two-thirds (66.7%) of ¹³⁷Cs-IR-exposed hearts revealed a linear pattern of gene expression (Figure 8A,B and Table 6). Further, dose–response shape-based clustering confirmed the predominantly linear response in ¹³⁷Cs-IR-exposed and non-linear responses in ¹⁴Si- and ²²Ti-IR-exposed hearts (Figure 8C,D).



Figure 8. Dose–response analyses of expression of 12 genes commonly deregulated in all three radiation conditions: (**A**,**B**) expression profile–exposure dosage analysis indicates that ¹³⁷Cs irradiation mostly causes linear changes in gene expression, while irradiation with ¹⁴Si and ²²Ti mainly induces a non-linear gene expression response. (**C**–**E**) Heatmap clustering of non-linear regression fit coefficients for 12 common genes in ¹³⁷Cs-, ¹⁴Si-, and ²²Ti-IR groups, respectively. The columns in heatmaps represent non-linear fit coefficients.

Icons		¹³⁷ Cs	¹⁴ Si	²² Ti
Type of Regression	Linear Regression	423	0	1
-)	Non-Linear Regression	215	53	123

 Table 6. Regression analyses of differentially expressed genes.

4. Discussion

We used archived mouse hearts from NASA's Space Radiation Tissue Sharing Forum collected from non-tumor-bearing female CB6F1/Hsd mice after single whole-body irradiation with different low or very low doses of ¹³⁷Cs-gamma, ¹⁴Si, or ²²Ti-ion IR to determine the long-term effects of radiation exposure on gene expression in the whole heart as a function of IR type and dose compared to sham-treated controls. We aimed to determine whether high-LET HZE particle-IR exposure may induce biological responses at lower doses compared to ¹³⁷Cs-gamma IR exposure. Our data revealed a dose-dependent increase in the number of DEGs (both up- and downregulated) following exposure to increasing doses of ¹³⁷Cs-IR, while no discernable pattern of DEGs was observed in hearts irradiated with ¹⁴Si or ²²Ti-ion. In contrast to ¹³⁷Cs-gamma IR, where the largest number of DEGs was observed after the highest dose (160 cGy), the largest number of DEGs was observed at the lowest dose of ¹⁴Si-IR (4 cGy) and the second-lowest dose of ²²Ti-IR (6.5 cGy), suggesting that compared to ¹³⁷Cs-gamma IR, even low doses of HZE-IR may be sufficient to induce long-term dysregulation of genes in the heart tissue. In the ¹⁴Si-ion IR group (260 MeV/n), no DEGs were detected at an intermediate dose of 16 cGy but were detected at the higher dose of 32 cGy, while the lowest number or absence of DEGs was observed at minimum and maximum doses of ²²Ti-ion IR (3 and 26 cGy, 1 GeV/n). It is possible the effects of these radiation types and respective doses may be too subtle for the detection of DEGs based on statistical criteria or may have resulted in extensive damage of a few heavily damaged cells at the cellular level, resulting in early death and clearance of the affected cells without long-term consequences on the gene expression in the whole tissue. Considering that low doses of HZE-ion IR may be sufficient to induce changes in genes involved in disease pathophysiology, further studies are needed to better delineate the effects of these radiation types and doses, along with the mechanisms triggering these varied responses, in order to develop better assessments of radiobiological effectiveness.

Among all groups, irrespective of radiation type or dose, no clear lower IR threshold for gene expression was detected. However, the gene signatures were indicative of varying cardiovascular diseases such as hypertension, atherosclerosis, cardiomyopathies (nonischemic, dilated, peripartum, hypertrophic), heart failure, acute myocardial injury, and myocarditis, as well as known cardiovascular risk factors, including but not limited to obstructive sleep apnea, idiopathic lung fibrosis, diabetes, and obesity. It is therefore of utmost importance to further investigate the disrupted pathways and linked gene networks to determine the presence of early biomarkers for disease risk and/or inform the development of mitigating factors for radiation-induced cardiovascular and other degenerative diseases during and after exploration-type spaceflight missions.

We identified 12 genes differentially regulated at at least one or more doses of all three radiation types. These include Spon2, Adam19, Arntl, Cdkn1a, Cry2, Per2, Per3, Wee1, Rcan1, Slc41a3, Errfi1, and Bhlhe41, which are related to numerous cardiovascular and degenerative diseases of other organs as well as varying aging processes. For example, Spon2 encodes mindin, an extracellular matrix protein highly expressed in cardiac tissue, and plays various roles, including (1) serving as a ligand for integrin during inflammation [37], (2) inhibiting angiogenesis [38], and (3) playing an anti-hypertrophic role, protecting against cardiac remodeling observed in heart failure by attenuating AKT/GSK3β and TGF-β1-Smad signaling [39]. We also found cyclin-dependent kinase inhibitor 1A (Cdkn1A), also known as p21, to be dysregulated with different radiation types/doses, which correlates with previously published reports [40]. P21 is a well-known potent universal CDK inhibitor [41] and regulates diverse biological functions such as cell growth, proliferation,

17 of 22

apoptosis, and inflammation [42,43]. It has been primarily described as a major regulator of p53-dependent cell cycle arrest in response to DNA damage. Previous aging studies reported that p21-knockout mice were more susceptible to developing spontaneous tumors and exhibited early tumor onset and more severe atherosclerotic lesions compared to wild-type mice [44,45].

Interestingly, among the 12 identified overlapping genes, 5 are directly related to the regulation of circadian rhythms: Per2, Per3, Cry2, Bhlhe41, and Arntl [46]. In addition to these circadian-rhythm-associated genes, we also identified the upstream transcription factor CLOCK [47], predicted to be upregulated across all radiation types/doses. The fundamental role of circadian rhythms is the diurnal regulation of behavior and physiological processes over 24 h, and they are of interest in spaceflight, considering the entrainment signals of light/dark are disrupted during low-Earth-orbit (LEO) flights [48] and are expected to be disrupted during future exploration-type space missions. Recent studies have highlighted the critical role of circadian rhythms in regulating cardiac metabolism, function, and response to injury [49].

The diurnal regulation of circadian rhythms involves feedback loops of transcription and translation. The CLOCK gene has DNA-binding histone acetyltransferase activity. It plays a critical role in regulating circadian rhythms by forming heterodimers with other clock proteins such as Arntl and promoting transcription of period (Per1, Per2, and Per3) [50] and cryptochrome (Cry1, Cry2) genes [46]. Per2 has been shown to play a cardioprotective role in myocardial ischemia. Its dysregulation is associated with increased cardiovascular disease risk as a result of impaired metabolic pathways, including fatty acid metabolism, cardiac anaerobic glycolysis, other pathways involved in vascular senescence and endothelial dysfunction, and dysregulation of cardiac ion channels, which play critical roles in the development of arrhythmias [51–55]. Such dysregulation may also result in the development of endothelial and vascular phenotypes observed in cardiovascular disease. Per3 is involved in delayed sleep-phase syndrome and cardiac autonomic control during sleep [56]. Considering its multifaceted regulatory roles, the disruption of circadian rhythms can potentially play a large role in many disease processes associated with lowdose space-type radiation.

We observed downregulation of Arntl with increasing doses of ¹³⁷Cs-gamma IR, whereas ¹⁴Si-ion IR exposure up to 8 cGy significantly upregulated Artnl. ²²Ti-ion IR did have a significant effect on Arntl expression at any dose. Differences in the radiation quality may be important to this observation as the silicon ions were 70 keV/mm, and the titanium were 100 keV/mm with greater ionization densities. Altered levels of Arntl have been associated with increased susceptibility to hypertension, diabetes, obesity, and defective lipogenesis [57,58]. Per3 expression dose-dependently followed ¹³⁷Cs-gamma IR, whereas higher doses of ¹⁴Si- ion IR (16 and 32 cGy) and ²²Ti-ion IR (greater than 6.5 cGy) exhibited increased Per3 expression. Furthermore, defects in Bhlhe41, a transcription factor repressor in circadian rhythms, are associated with altered sleep patterns [59] and are reported to play a significant role in immune function [60], as well as epithelial-tomesenchymal transition [61]. Bhlhe41 expression was elevated at all ¹³⁷Cs-gamma IR doses, whereas no effect on expression was noted across all doses of ¹⁴Si-ion IR. Higher doses of ²²Ti-ion IR (6.5–26 cGy) significantly increased Bhlhe41 expression. The differential regulation of CLOCK genes can disrupt components downstream to the circadian cycle regulatory mechanism. Thus, regulation of the circadian rhythm genes may represent a potential mitigation mechanism for the well-being of astronauts during long-duration space missions [62].

In addition to CLOCK, our gene enrichment analysis identified nine other transcriptions factors (TCF21, AR, SLAL4, SMAD2, SMAD3, OOAR, OCT4, CDX2, and CEBPB), which are implicated in various cellular processes, including metabolism [63,64], inflammation [65–67], rhythmic activation of circadian cycle repressors [68], and maintenance of the pluripotency of stem cells [69–72]. Many of these factors act as key mediators of canonical signaling pathways such as SMAD2 and SMAD3, involved in TGF-β signaling. They, thus,

18 of 22

are involved in cell proliferation, apoptosis, and differentiation [73–76]. Additionally, many play important roles in tumor processes, including tumor-associated angiogenesis and induction of epithelial-to-mesenchymal cell transitioning [77–82]. Thus, there are many potential avenues to explore to understand and mitigate the cardiovascular response in the setting of radiation exposure during spaceflight.

There are few limitations worth mentioning. First, we used a relaxed cutoff threshold (adjusted p < 0.25), which could include more false positives compared to a stricter cutoff. In contrast, it is well known that a small sample size generally yields higher adjusted p-values [83–86]. However, the results of downstream functional analyses and data from previous publications further confirmed the validity of our methodology and findings.

5. Conclusions

In this study, we demonstrated that exposure to ionizing radiation causes a change in the transcriptomic profile of hearts from whole-body-irradiated mouse hearts that is dependent on the quality and quantity of radiation. The effects of low-LET ¹³⁷Cs-gamma rays and high-LET ¹⁴Si- and ²²Ti-ion IR are distinctly different, yet none presented a clear lower IR threshold for differential gene expression in this study. Dose-dependent regression analyses of the 12 identified differentially expressed common genes for all three radiation types showed a dose-dependent linear response in 67% (8/12) of the genes following ¹³⁷Cs-gamma IR, consistent with changes induced in the whole transcriptomic profile after this type of IR exposure. At the same time, there was an exclusive non-linear DEG pattern with ¹⁴Si- or ²²Ti-ion IR. Moreover, HZE-ion IR-exposed hearts showed the largest change in gene expression at lower doses, indicating a greater biological response at low and very low doses, in part, due to the different quality of HZE-ion IR-induced tissue damage. Multiple genes involved in cardiovascular and other degenerative diseases were attenuated with exposure to all three radiation types. Overall, the data in this manuscript points to metrics in the form of differential gene expression that could be used in assessing cardiovascular risks astronauts face during deep-space missions but also risks for other neurodegenerative diseases, aging processes, and cancers of various organs. However, future mechanistic and functional studies, including acute, intermediate, and late time points using additional lower doses to determine a possible lower threshold, would give us a comprehensive understanding of HZE-ion IR's effects on human health and disease.

Supplementary Materials: The following are available online at https://www.mdpi.com/2073-440 9/10/2/387/s1: Supplementary Figure S1: Comparison and selection of batch adjustment methods for microarray analysis; Supplementary Figure S2: Mean irradiation exposure-related transcriptome portraits; Supplementary Figure S3: PCA of batch-adjusted gene expression matrix; Supplementary Figure S4: Overlapping DEGs and functional terms between particle doses causing the maximal effect (¹³⁷Cs at 160 cGy, ¹⁴Si at 4cGy, and ²²Ti at 6.5 cGy); Supplementary Table S1; Supplementary Table S2; Supplementary Table S3; Supplementary Table S4; Supplementary Table S5; and Supplementary Table S6.

Author Contributions: Conceptualization, E.A.B., P.Y.C., and D.A.G.; data curation, M.K.K., R.K., and D.A.G.; formal analysis, V.N.S.G., A.A., A.B. (Anamika Bajpai), K.M.F., and D.A.G.; funding acquisition, E.A.B., P.Y.C., and D.A.G.; investigation, E.A.B., P.Y.C., and D.A.G.; methodology, V.N.S.G., A.A., M.M.T., S.A., and M.B.; project administration, E.A.B., P.Y.C., and D.A.G.; resources, A.A., S.A., and D.A.G.; software, A.A.; supervision, E.A.B., P.Y.C., and D.A.G.; validation, M.M.T., M.C., V.M., A.B. (Anamika Bajpai), and S.A.; writing–original draft, V.N.S.G., M.B., A.B. (Agnieszka Brojakowska), A.E., L.H., and D.A.G.; writing–review and editing, V.N.S.G., E.A.B., P.Y.C., M.B., M.K.K., L.H., R.K., and D.A.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by NASA grant no. 80NSSC19K1078 (formerly 80NSSC17K0112) to D.A.G. and by NASA grant no. NNJ11HA94I to E.B. and P.C, under contract DEAC02-05CH11231 with the US Department of Energy. Additional support was provided in part by NASA grant no. 80NSSC19K1079 (formerly 80NSSC18K0921) to D.A.G. and by NIH National Heart, Lung, and Blood Institute (NHLBI) grant nos. HL091983, HL143892, and HL134608t to R.K. The funders had no role in study design, data collection, and analysis, the decision to publish, or manuscript preparation.

Institutional Review Board Statement: All procedures were compliant with the standards of the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health and approved by the Animal Care and Use Committees at Lawrence Berkeley National Laboratory (Berkeley, CA, USA), Brookhaven National Laboratory (BNL) (Upton, NY, USA), and SRI International (Menlo Park, CA, USA).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are openly available in Gene Expression Omnibus (GEO), with the accession number GSE164234.

Acknowledgments: We thank Eleanor Blakely and Polly Chang and their corresponding team members for sharing their unique experimental samples with our research group through the NASA Space Radiation Tissue Sharing Forum.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Czupalla, M.; Horneck, G.; Blome, H.J. The conceptual design of a hybrid life support system based on the evaluation and comparison of terrestrial testbeds. *Adv. Space Res. Off. J. Comm. Space Res.* (COSPAR) 2005, 35, 1609–1620. [CrossRef] [PubMed]
- 2. Demontis, G.C.; Germani, M.M.; Caiani, E.G.; Barravecchia, I.; Passino, C.; Angeloni, D. Human Pathophysiological Adaptations to the Space Environment. *Front. Physiol.* **2017**, *8*, 547. [CrossRef] [PubMed]
- 3. Reitz, G. Characteristic of the radiation field in low Earth orbit and in deep space. *Z. Med. Phys.* **2008**, *18*, 233–243. [CrossRef] [PubMed]
- 4. Norbury, J.W.; Schimmerling, W.; Slaba, T.C.; Azzam, E.I.; Badavi, F.F.; Baiocco, G.; Benton, E.; Bindi, V.; Blakely, E.A.; Blattnig, S.R.; et al. Galactic cosmic ray simulation at the NASA Space Radiation Laboratory. *Life Sci. Space Res.* **2016**, *8*, 38–51. [CrossRef]
- 5. Council, N.R. *Recapturing a Future for Space Exploration: Life and Physical Sciences Research for a New Era;* The National Academies Press: Washington, DC, USA, 2011. [CrossRef]
- Shtifman, A.; Pezone, M.J.; Sasi, S.P.; Agarwal, A.; Gee, H.; Song, J.; Perepletchikov, A.; Yan, X.; Kishore, R.; Goukassian, D.A. Divergent modification of low-dose ⁵⁶Fe-particle and proton radiation on skeletal muscle. *Radiat. Res.* 2013, 180, 455–464. [CrossRef]
- Sasi, S.P.; Song, J.; Park, D.; Enderling, H.; McDonald, J.T.; Gee, H.; Garrity, B.; Shtifman, A.; Yan, X.; Walsh, K.; et al. TNF-TNFR2/p75 signaling inhibits early and increases delayed nontargeted effects in bone marrow-derived endothelial progenitor cells. J. Biol. Chem. 2015, 290, 27014. [CrossRef] [PubMed]
- 8. Delius, W.; Senbening, H.; Wirtzfeld, A.; Lutilsky, L. Atrial stimulation in the therapy of auricular flutter. *Mmwmunchener Med. Wochenschr.* **1974**, *116*, 479–484.
- Sasi, S.P.; Park, D.; Muralidharan, S.; Wage, J.; Kiladjian, A.; Onufrak, J.; Enderling, H.; Yan, X.; Goukassian, D.A. Particle Radiation-Induced Nontargeted Effects in Bone-Marrow-Derived Endothelial Progenitor Cells. *Stem Cells Int.* 2015, 2015, 496512. [CrossRef] [PubMed]
- Coleman, M.A.; Sasi, S.P.; Onufrak, J.; Natarajan, M.; Manickam, K.; Schwab, J.; Muralidharan, S.; Peterson, L.E.; Alekseyev, Y.O.; Yan, X.; et al. Low-dose radiation affects cardiac physiology: Gene networks and molecular signaling in cardiomyocytes. *Am. J. Physiol. Heart Circ. Physiol.* 2015, 309, H1947–H1963. [CrossRef]
- 11. Chang, P.Y.; Cucinotta, F.A.; Bjornstad, K.A.; Bakke, J.; Rosen, C.J.; Du, N.; Fairchild, D.G.; Cacao, E.; Blakely, E.A. Harderian Gland Tumorigenesis: Low-Dose and LET Response. *Radiat. Res.* **2016**, *185*, 449–460. [CrossRef]
- 12. Leek, J.T.; Johnson, W.E.; Parker, H.S.; Jaffe, A.E.; Storey, J.D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* **2012**, *28*, 882–883. [CrossRef]
- 13. Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **2015**, *43*, e47. [CrossRef] [PubMed]
- 14. Oytam, Y.; Sobhanmanesh, F.; Duesing, K.; Bowden, J.C.; Osmond-McLeod, M.; Ross, J. Risk-conscious correction of batch effects: Maximising information extraction from high-throughput genomic datasets. *BMC Bioinform.* **2016**, *17*, 332. [CrossRef]
- Li, J.; Bushel, P.; Chu, T.-M.; Wolfinger, R. Principal Variance Components Analysis: Estimating Batch Effects in Microarray Gene Expression Data. In *Batch Effects and Noise in Microarray Experiments: Sources and Solutions*; Wiley: Hoboken, NJ, USA, 2009; pp. 141–154. [CrossRef]
- Kuleshov, M.V.; Jones, M.R.; Rouillard, A.D.; Fernandez, N.F.; Duan, Q.; Wang, Z.; Koplev, S.; Jenkins, S.L.; Jagodnik, K.M.; Lachmann, A.; et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* 2016, 44, W90–W97. [CrossRef] [PubMed]
- 17. Loffler-Wirth, H.; Kalcher, M.; Binder, H. oposSOM: R-package for high-dimensional portraying of genome-wide expression landscapes on bioconductor. *Bioinformatics* 2015, *31*, 3225–3227. [CrossRef]
- 18. Wirth, H.; Loffler, M.; von Bergen, M.; Binder, H. Expression cartography of human tissues using self organizing maps. BMC Bioinform. 2011, 12, 306. [CrossRef]

- Kusano, K.F.; Pola, R.; Murayama, T.; Curry, C.; Kawamoto, A.; Iwakura, A.; Shintani, S.; Ii, M.; Asai, J.; Tkebuchava, T.; et al. Sonic hedgehog myocardial gene therapy: Tissue repair through transient reconstitution of embryonic signaling. *Nat. Med.* 2005, 11, 1197–1204. [CrossRef]
- 20. Preitner, N.; Damiola, F.; Lopez-Molina, L.; Zakany, J.; Duboule, D.; Albrecht, U.; Schibler, U. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. *Cell* **2002**, *110*, 251–260. [CrossRef]
- 21. Lopez-Molina, L.; Conquet, F.; Dubois-Dauphin, M.; Schibler, U. The DBP gene is expressed according to a circadian rhythm in the suprachiasmatic nucleus and influences circadian behavior. *EMBO J.* **1997**, *16*, 6762–6771. [CrossRef]
- 22. Yeh, C.M.; Shay, J.; Zeng, T.C.; Chou, J.L.; Huang, T.H.; Lai, H.C.; Chan, M.W. Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer. *Int. J. Oncol.* **2014**, *45*, 2101–2107. [CrossRef] [PubMed]
- Li, Q.; Zhou, X.; Fang, Z.; Pan, Z. Effect of STC2 gene silencing on colorectal cancer cells. *Mol. Med. Rep.* 2019, 20, 977–984. [CrossRef]
- Hayashi, T.; Arimura, T.; Itoh-Satoh, M.; Ueda, K.; Hohda, S.; Inagaki, N.; Takahashi, M.; Hori, H.; Yasunami, M.; Nishi, H.; et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J. Am. Coll. Cardiol. 2004, 44, 2192–2201. [CrossRef]
- 25. Amoroso, F.; Falzoni, S.; Adinolfi, E.; Ferrari, D.; Di Virgilio, F. The P2X7 receptor is a key modulator of aerobic glycolysis. *Cell Death Dis.* **2012**, *3*, e370. [CrossRef]
- 26. Chen, Y.; Chen, X.; Gao, J.; Xu, C.; Xu, P.; Li, Y.; Zhu, Y.; Yu, C. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway. *FASEB J.* **2019**, *33*, 11411–11419. [CrossRef]
- 27. Tan, K.L.; Board, P.G. Purification and characterization of a recombinant human Theta-class glutathione transferase (GSTT2-2). *Biochem. J.* **1996**, *315 Pt 3*, 727–732. [CrossRef]
- 28. Marnett, L.J. Oxy radicals, lipid peroxidation and DNA damage. Toxicology 2002, 181–182, 219–222. [CrossRef]
- Landi, S.; Gemignani, F.; Moreno, V.; Gioia-Patricola, L.; Chabrier, A.; Guino, E.; Navarro, M.; de Oca, J.; Capella, G.; Canzian, F.; et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. *Pharm. Genom.* 2005, 15, 535–546. [CrossRef] [PubMed]
- Rissiek, B.; Haag, F.; Boyer, O.; Koch-Nolte, F.; Adriouch, S. P2X7 on Mouse T Cells: One Channel, Many Functions. *Front. Immunol.* 2015, 6, 204. [CrossRef] [PubMed]
- 31. Chen, Y.; Wang, J.; Wang, X.; Li, X.; Song, J.; Fang, J.; Liu, X.; Liu, T.; Wang, D.; Li, Q.; et al. Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity. *Clin. Cancer Res.* **2019**, *25*, 6180–6194. [CrossRef]
- 32. Chen, W.N.; Zhu, G.J. Progress in the research of stanniocalcin. Sheng Li Ke Xue Jin Zhan 2008, 39, 225–228.
- 33. Douglas, R.; Kellaway, L.; Mintz, M.; van Wageningen, G. The crossed nigrostriatal projection decussates in the ventral tegmental decussation. *Brain Res.* **1987**, *418*, 111–121. [CrossRef]
- 34. He, X.; Zhu, Z.; Johnson, C.; Stoops, J.; Eaker, A.E.; Bowen, W.; DeFrances, M.C. PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. *Cancer Res.* **2008**, *68*, 5591–5598. [CrossRef]
- 35. Yu, M.; Li, W.; Wang, Q.; Wang, Y.; Lu, F. Circadian regulator NR1D2 regulates glioblastoma cell proliferation and motility. Oncogene 2018, 37, 4838–4853. [CrossRef]
- Xu, M.; Wang, Y.; He, H.T.; Yang, Q. MiR-589-5p is a potential prognostic marker of hepatocellular carcinoma and regulates tumor cell growth by targeting MIG-6. *Neoplasma* 2018, 65, 753–761. [CrossRef]
- 37. Jia, W.; Li, H.; He, Y.W. The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. *Blood* **2005**, *106*, 3854–3859. [CrossRef] [PubMed]
- Feinstein, Y.; Klar, A. The neuronal class 2 TSR proteins F-spondin and Mindin: A small family with divergent biological activities. *Int. J. Biochem. Cell Biol.* 2004, 36, 975–980. [CrossRef] [PubMed]
- Yan, L.; Wei, X.; Tang, Q.Z.; Feng, J.; Zhang, Y.; Liu, C.; Bian, Z.Y.; Zhang, L.F.; Chen, M.; Bai, X.; et al. Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3beta and TGF-beta1-Smad signalling. *Cardiovasc. Res.* 2011, 92, 85–94. [CrossRef] [PubMed]
- Badie, C.; Dziwura, S.; Raffy, C.; Tsigani, T.; Alsbeih, G.; Moody, J.; Finnon, P.; Levine, E.; Scott, D.; Bouffler, S. Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment. *Br. J. Cancer* 2008, *98*, 1845–1851. [CrossRef] [PubMed]
- 41. Gartel, A.L.; Serfas, M.S.; Tyner, A.L. p21—Negative regulator of the cell cycle. *Proc. Soc. Exp. Biol. Med.* **1996**, 213, 138–149. [CrossRef] [PubMed]
- 42. Harper, J.W.; Adami, G.R.; Wei, N.; Keyomarsi, K.; Elledge, S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. *Cell* **1993**, *75*, 805–816. [CrossRef]
- Scatizzi, J.C.; Mavers, M.; Hutcheson, J.; Young, B.; Shi, B.; Pope, R.M.; Ruderman, E.M.; Samways, D.S.K.; Corbett, J.A.; Egan, T.M.; et al. The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages. *Eur. J. Immunol.* 2009, 39, 820–825. [CrossRef] [PubMed]
- 44. Martin-Caballero, J.; Flores, J.M.; Garcia-Palencia, P.; Serrano, M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. *Cancer Res.* 2001, *61*, 6234–6238.
- 45. Khanna, A.K. Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis. *J. Biomed. Sci.* **2009**, *16*, 66. [CrossRef] [PubMed]

- 46. Brown, S.A. Circadian clock-mediated control of stem cell division and differentiation: Beyond night and day. *Development* **2014**, 141, 3105–3111. [CrossRef]
- 47. Brown, S.A.; Kowalska, E.; Dallmann, R. (Re)inventing the circadian feedback loop. Dev. Cell 2012, 22, 477–487. [CrossRef]
- 48. Mallis, M.M.; DeRoshia, C.W. Circadian rhythms, sleep, and performance in space. Aviat. Space Environ. Med. 2005, 76, B94–B107.
- 49. Chellappa, S.L.; Vujovic, N.; Williams, J.S.; Scheer, F. Impact of Circadian Disruption on Cardiovascular Function and Disease. *Trends Endocrinol. Metab.* **2019**, *30*, 767–779. [CrossRef]
- Koczor, C.A.; Ludlow, I.; Hight, R.S., 2nd; Jiao, Z.; Fields, E.; Ludaway, T.; Russ, R.; Torres, R.A.; Lewis, W. Ecstasy (MDMA) Alters Cardiac Gene Expression and DNA Methylation: Implications for Circadian Rhythm Dysfunction in the Heart. *Toxicol. Sci.* Off. J. Soc. Toxicol. 2015, 148, 183–191. [CrossRef]
- 51. Bonney, S.; Hughes, K.; Harter, P.N.; Mittelbronn, M.; Walker, L.; Eckle, T. Cardiac period 2 in myocardial ischemia: Clinical implications of a light dependent protein. *Int. J. Biochem. Cell Biol.* **2013**, *45*, 667–671. [CrossRef]
- 52. Eckle, T.; Hartmann, K.; Bonney, S.; Reithel, S.; Mittelbronn, M.; Walker, L.A.; Lowes, B.D.; Han, J.; Borchers, C.H.; Buttrick, P.M.; et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. *Nat. Med.* **2012**, *18*, 774–782. [CrossRef] [PubMed]
- 53. Wang, C.Y.; Wen, M.S.; Wang, H.W.; Hsieh, I.C.; Li, Y.; Liu, P.Y.; Lin, F.C.; Liao, J.K. Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. *Circulation* **2008**, *118*, 2166–2173. [CrossRef]
- 54. Grimaldi, B.; Bellet, M.M.; Katada, S.; Astarita, G.; Hirayama, J.; Amin, R.H.; Granneman, J.G.; Piomelli, D.; Leff, T.; Sassone-Corsi, P. PER2 controls lipid metabolism by direct regulation of PPARgamma. *Cell Metab.* **2010**, *12*, 509–520. [CrossRef]
- 55. Jeyaraj, D.; Haldar, S.M.; Wan, X.; McCauley, M.D.; Ripperger, J.A.; Hu, K.; Lu, Y.; Eapen, B.L.; Sharma, N.; Ficker, E.; et al. Circadian rhythms govern cardiac repolarization and arrhythmogenesis. *Nature* **2012**, *483*, 96–99. [CrossRef]
- 56. Arai, S.; Meagher, R.; Swearingen, M.; Myint, H.; Rich, E.; Martinson, J.; Klingemann, H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. *Cytotherapy* **2008**, *10*, 625–632. [CrossRef] [PubMed]
- 57. Angelousi, A.; Kassi, E.; Nasiri-Ansari, N.; Weickert, M.O.; Randeva, H.; Kaltsas, G. Clock genes alterations and endocrine disorders. *Eur. J. Clin. Investig.* **2018**, *48*, e12927. [CrossRef] [PubMed]
- 58. Chen, E.Y.; Tan, C.M.; Kou, Y.; Duan, Q.; Wang, Z.; Meirelles, G.V.; Clark, N.R.; Ma'ayan, A. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinform.* **2013**, *14*, 128. [CrossRef] [PubMed]
- 59. Rijo-Ferreira, F.; Takahashi, J.S. Genomics of circadian rhythms in health and disease. *Genome Med.* **2019**, *11*, 82. [CrossRef] [PubMed]
- 60. Samten, B. Regulation of B-1a cells: Another novel function of the basic helix-loop-helix transcriptional regulator BHLHE41. *Cell. Mol. Immunol.* **2017**, *14*, 802–804. [CrossRef]
- 61. Asanoma, K.; Liu, G.; Yamane, T.; Miyanari, Y.; Takao, T.; Yagi, H.; Ohgami, T.; Ichinoe, A.; Sonoda, K.; Wake, N.; et al. Regulation of the Mechanism of TWIST1 Transcription by BHLHE40 and BHLHE41 in Cancer Cells. *Mol. Cell. Biol.* **2015**, *35*, 4096–4109. [CrossRef]
- 62. Flynn-Evans, E.E.; Barger, L.K.; Kubey, A.A.; Sullivan, J.P.; Czeisler, C.A. Circadian misalignment affects sleep and medication use before and during spaceflight. *NPJ Microgravity* **2016**, *2*, 15019. [CrossRef]
- 63. Tyagi, S.; Gupta, P.; Saini, A.S.; Kaushal, C.; Sharma, S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. *J. Adv. Pharm. Technol. Res.* 2011, 2, 236–240. [CrossRef]
- 64. De Filippis, D.; D'Amico, A.; Cinelli, M.P.; Esposito, G.; Di Marzo, V.; Iuvone, T. Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats. *J. Cell. Mol. Med.* **2009**, *13*, 1086–1095. [CrossRef] [PubMed]
- 65. Zahid, M.D.K.; Rogowski, M.; Ponce, C.; Choudhury, M.; Moustaid-Moussa, N.; Rahman, S.M. CCAAT/enhancer-binding protein beta (C/EBPbeta) knockdown reduces inflammation, ER stress, and apoptosis, and promotes autophagy in oxLDL-treated RAW264.7 macrophage cells. *Mol. Cell. Biochem.* **2020**, *463*, 211–223. [CrossRef]
- 66. Tang, Q.Q.; Otto, T.C.; Lane, M.D. CCAAT/enhancer-binding protein beta is required for mitotic clonal expansion during adipogenesis. *Proc. Natl. Acad. Sci. USA* 2003, 100, 850–855. [CrossRef] [PubMed]
- 67. Giltiay, N.V.; Karakashian, A.A.; Alimov, A.P.; Ligthle, S.; Nikolova-Karakashian, M.N. Ceramide- and ERK-dependent pathway for the activation of CCAAT/enhancer binding protein by interleukin-1beta in hepatocytes. *J. Lipid Res.* 2005, *46*, 2497–2505. [CrossRef]
- 68. Menet, J.S.; Pescatore, S.; Rosbash, M. CLOCK:BMAL1 is a pioneer-like transcription factor. Genes Dev. 2014, 28, 8–13. [CrossRef]
- 69. Xie, Y.; Martin, K.A. TCF21: Flipping the Phenotypic Switch in SMC. Circ. Res. 2020, 126, 530–532. [CrossRef]
- Zhang, J.; Tam, W.L.; Tong, G.Q.; Wu, Q.; Chan, H.Y.; Soh, B.S.; Lou, Y.; Yang, J.; Ma, Y.; Chai, L.; et al. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. *Nat. Cell Biol.* 2006, *8*, 1114–1123. [CrossRef]
- 71. Zeineddine, D.; Hammoud, A.A.; Mortada, M.; Boeuf, H. The Oct4 protein: More than a magic stemness marker. *Am. J. Stem Cells* **2014**, *3*, 74–82.
- 72. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **2006**, *126*, 663–676. [CrossRef] [PubMed]
- 73. Zi, Z.; Chapnick, D.A.; Liu, X. Dynamics of TGF-beta/Smad signaling. *FEBS Lett.* 2012, 586, 1921–1928. [CrossRef]
- 74. Hata, A.; Chen, Y.G. TGF-beta Signaling from Receptors to Smads. Cold Spring Harb. Perspect. Biol. 2016, 8. [CrossRef]

- 75. Massague, J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616–630. [CrossRef]
- 76. Cohen, P. Molecular mechanisms involved in the control of glycogenolysis in skeletal muscle by calcium ions and cyclic AMP. *Biochem. Soc. Trans.* **1987**, *15*, 999–1001. [CrossRef] [PubMed]
- 77. Tan, M.H.; Li, J.; Xu, H.E.; Melcher, K.; Yong, E.L. Androgen receptor: Structure, role in prostate cancer and drug discovery. *Acta Pharmacol. Sin.* **2015**, *36*, 3–23. [CrossRef] [PubMed]
- 78. Takakura, Y.; Hinoi, T.; Oue, N.; Sasada, T.; Kawaguchi, Y.; Okajima, M.; Akyol, A.; Fearon, E.R.; Yasui, W.; Ohdan, H. CDX2 regulates multidrug resistance 1 gene expression in malignant intestinal epithelium. *Cancer Res.* 2010, 70, 6767–6778. [CrossRef] [PubMed]
- Yu, J.; Liu, D.; Sun, X.; Yang, K.; Yao, J.; Cheng, C.; Wang, C.; Zheng, J. CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/beta-catenin signaling via transactivation of GSK-3beta and Axin2 expression. *Cell Death Dis.* 2019, 10, 26. [CrossRef] [PubMed]
- 80. Schreiber, E.; Matthias, P.; Muller, M.M.; Schaffner, W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. *Nucleic Acids Res.* **1989**, *17*, 6419. [CrossRef]
- 81. Koo, B.S.; Lee, S.H.; Kim, J.M.; Huang, S.; Kim, S.H.; Rho, Y.S.; Bae, W.J.; Kang, H.J.; Kim, Y.S.; Moon, J.H.; et al. Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. *Oncogene* **2015**, *34*, 2317–2324. [CrossRef]
- 82. Zhang, X.; Zhang, P.; Shao, M.; Zang, X.; Zhang, J.; Mao, F.; Qian, H.; Xu, W. SALL4 activates TGF-beta/SMAD signaling pathway to induce EMT and promote gastric cancer metastasis. *Cancer Manag. Res.* **2018**, *10*, 4459–4470. [CrossRef]
- Pawitan, Y.; Michiels, S.; Koscielny, S.; Gusnanto, A.; Ploner, A. False discovery rate, sensitivity and sample size for microarray studies. *Bioinformatics* 2005, 21, 3017–3024. [CrossRef] [PubMed]
- 84. Liu, P.; Hwang, J.T. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis. *Bioinformatics* **2007**, *23*, 739–746. [CrossRef] [PubMed]
- 85. Tod, P.; Roka, B.; Kaucsar, T.; Szatmari, K.; Vizovisek, M.; Vidmar, R.; Fonovic, M.; Szenasi, G.; Hamar, P. Time-Dependent miRNA Profile during Septic Acute Kidney Injury in Mice. *Int. J. Mol. Sci.* **2020**, *21*, 5316. [CrossRef] [PubMed]
- 86. Jiang, D.; Xie, X.; Lu, Z.; Liu, L.; Qu, Y.; Wu, S.; Li, Y.; Li, G.; Wang, H.; Xu, G. Establishment of a Colorectal Cancer-Related MicroRNA-mRNA Regulatory Network by Microarray and Bioinformatics. *Front. Genet.* **2020**, *11*, 560186. [CrossRef]